The risk of incident gout according to SUA category, overall and by sex, from prospective population-based studies.
| Study | Followup, Yrs | SUA Category, mg/dl | Overall | Males | Females | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases, n | IR | IRR (95% CI) | Cases, n | IR | IRR (95% CI) | Cases, n | IR | IRR (95% CI) | |||
| Campion, et al29,a,* | 14.9 | ≤ 6 | 10 | 0.8 | Referent | — | — | — | |||
| 6.0–6.9 | 13 | 0.9 | 1.1 (0.3–2.0) | — | — | — | |||||
| 7.0–7.9 | 21 | 4.1 | 5.1 (4.4–5.9) | — | — | — | |||||
| 8.0–8.9 | 14 | 8.4 | 10.5 (9.7–11.3) | — | — | — | |||||
| 9.0–9.9 | 18 | 43.2 | 54.0 (53.2–54.8) | — | — | — | |||||
| ≥ 10.0 | 8 | 70.2 | 87.8 (86.8–88.7) | — | — | — | |||||
| Bhole, et al16,b | 28 | < 5 | 63 | 0.8 | — | 17 | 0.8 | Referent | 46 | 0.8 | Referent |
| 5–5.9 | 81 | 3.0 | — | 56 | 3.4 | 4.1 (2.4–7.1) | 25 | 2.5 | 2.4 (1.5–4.0) | ||
| 6–6.9 | 78 | 6.1 | — | 64 | 8 | 9.5 (5.5–16.6) | 14 | 4.2 | 3.4 (1.8–6.6) | ||
| 7–7.9 | 54 | 15.5 | — | 42 | 17.8 | 22.4 (12.3–40.6) | 12 | 13.1 | 12.2 (5.9–25.3) | ||
| ≥ 8 | 28 | 30.1 | — | 21 | 32.9 | 47.9 (24.0–95.5) | 7 | 27.3 | 22.5 (9.1–55.6) | ||
| Chen, et al30,* | 7.3 | < 6 | — | 1.5 | — | — | 2.3 | Referent | — | 0.7 | Referent |
| 6–9 | — | 5.7 | — | — | 7.4 | 3.2 (NR) | — | 4.1 | 6.1 (NR) | ||
| > 9 | — | 28.7 | — | — | 38.4 | 16.5 (NR) | — | 19.0 | 28.7 (NR) | ||
↵a Most recent SUA was presented; SUA was measured every 5 years.
↵b Authors presented adjusted HR of developing gout rather than IRR.
↵* Crude rate ratio was calculated based on presented data. For Chen, et al30, 95% CI were not calculated because SUA category-specific n were unknown. SUA: serum uric acid; IR: incidence rate (per 1000 person-yrs); IRR: incidence rate ratio; NR: not reported.